Posted on June 3, 2022
JRDF will fund the project “Investigating Combinatorial Use of Inhibitors of Focal Adhesion Kinase and PFKFB3 for Reversal of Type 1 Diabetes (T1D),” on which Jon D. Piganelli, PhD, is the principal investigator and Farzad Esni, PhD, is co-investigator. Here, the investigators aim to advance the pursuit of a treatment for T1D without undesirable side effects by testing a gene therapy approach in diabetic mice. Their ultimate goal is to progress towards clinical trials in humans with diabetes.